Zoetis Inc. (NYSE:ZTS) Receives Consensus Rating of “Hold” from Analysts

Shares of Zoetis Inc. (NYSE:ZTS) have been assigned a consensus rating of “Hold” from the fifteen research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $133.9167.

A number of analysts recently issued reports on the company. Bank of America lifted their target price on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Argus restated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. UBS Group cut their price objective on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Finally, BTIG Research reissued a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research note on Thursday, February 26th.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Investors are refocusing on Zoetis’ longer-term growth story, including its precision-animal-health expansion and planned Neogen animal genomics acquisition, which may be helping the stock rebound.
• Positive Sentiment: Unusual options activity showed increased call buying in ZTS, suggesting some traders are positioning for more upside.
• Neutral Sentiment: Zoetis released its 2025 Sustainability Report, highlighting progress in its “Driven to Care” strategy; this supports the company’s long-term narrative but is unlikely to move the stock much on its own. Article Title
• Negative Sentiment: Multiple law firms announced or expanded securities class action efforts against Zoetis, alleging investors were harmed by concealed FDA safety warnings and competitive market-share erosion; these headlines can weigh on the stock by raising legal and reputational risk. Article Title
• Negative Sentiment: Recent commentary also highlighted Zoetis’ underperformance versus healthcare peers and criticism from commentators, adding to the cautious tone around the name. Article Title

Zoetis Stock Performance

Shares of ZTS opened at $79.59 on Friday. The stock has a market capitalization of $33.37 billion, a price-to-earnings ratio of 13.20, a PEG ratio of 1.27 and a beta of 0.75. Zoetis has a 12 month low of $72.38 and a 12 month high of $171.52. The firm has a fifty day simple moving average of $101.26 and a 200 day simple moving average of $115.80. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same period last year, the firm earned $1.48 earnings per share. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Research analysts forecast that Zoetis will post 6.89 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is 35.16%.

Insider Transactions at Zoetis

In other news, Director Paul Bisaro bought 2,000 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the acquisition, the director owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Frank A. Damelio bought 6,650 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the purchase, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 11,650 shares of company stock worth $886,384 in the last ninety days. Insiders own 0.22% of the company’s stock.

Institutional Trading of Zoetis

A number of hedge funds have recently made changes to their positions in the business. Global Wealth Strategies & Associates acquired a new position in shares of Zoetis during the 4th quarter worth approximately $25,000. Prosperity Bancshares Inc acquired a new stake in Zoetis during the 4th quarter valued at $25,000. Cassaday & Co Wealth Management LLC bought a new position in Zoetis during the first quarter worth $28,000. Lodestone Wealth Management LLC bought a new position in Zoetis during the fourth quarter worth $30,000. Finally, Root Financial Partners LLC increased its holdings in shares of Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.